Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
Go back to Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 127.16 -0.46 (0.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $127.62 | 52 Week High | $118.49 | |||
| Open | $127.85 | 52 Week Low | $55.00 | |||
| Day High | $128.72 | P/E | N/A | |||
| Day Low | $126.88 | EPS | $-0.56 | |||
| Volume | 570,917 | |||||
